RS64156B1 - Oksazinski inhibitori monoacilglicerol lipaze (magl) - Google Patents
Oksazinski inhibitori monoacilglicerol lipaze (magl)Info
- Publication number
- RS64156B1 RS64156B1 RS20230303A RSP20230303A RS64156B1 RS 64156 B1 RS64156 B1 RS 64156B1 RS 20230303 A RS20230303 A RS 20230303A RS P20230303 A RSP20230303 A RS P20230303A RS 64156 B1 RS64156 B1 RS 64156B1
- Authority
- RS
- Serbia
- Prior art keywords
- magl
- oxazine
- inhibitors
- monoacylglycerol lipase
- monoacylglycerol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163273 | 2018-03-22 | ||
| CN2019075372 | 2019-02-18 | ||
| EP19711920.9A EP3768684B1 (en) | 2018-03-22 | 2019-03-22 | Oxazine monoacylglycerol lipase (magl) inhibitors |
| PCT/EP2019/057174 WO2019180185A1 (en) | 2018-03-22 | 2019-03-22 | Oxazine monoacylglycerol lipase (magl) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64156B1 true RS64156B1 (sr) | 2023-05-31 |
Family
ID=65818027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230303A RS64156B1 (sr) | 2018-03-22 | 2019-03-22 | Oksazinski inhibitori monoacilglicerol lipaze (magl) |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210107920A1 (sr) |
| EP (1) | EP3768684B1 (sr) |
| JP (1) | JP7308220B2 (sr) |
| KR (1) | KR20200136425A (sr) |
| CN (1) | CN111936503B (sr) |
| AU (1) | AU2019238381B2 (sr) |
| BR (1) | BR112020014992A2 (sr) |
| CA (1) | CA3089443A1 (sr) |
| CL (1) | CL2020002423A1 (sr) |
| CO (1) | CO2020009567A2 (sr) |
| CR (1) | CR20200416A (sr) |
| DK (1) | DK3768684T3 (sr) |
| ES (1) | ES2942319T3 (sr) |
| FI (1) | FI3768684T3 (sr) |
| HR (1) | HRP20230388T1 (sr) |
| HU (1) | HUE061584T2 (sr) |
| IL (1) | IL276031B2 (sr) |
| LT (1) | LT3768684T (sr) |
| MX (1) | MX2020008894A (sr) |
| PE (1) | PE20201185A1 (sr) |
| PH (1) | PH12020500661A1 (sr) |
| PL (1) | PL3768684T3 (sr) |
| RS (1) | RS64156B1 (sr) |
| SG (1) | SG11202007608UA (sr) |
| SI (1) | SI3768684T1 (sr) |
| TW (1) | TWI818967B (sr) |
| WO (1) | WO2019180185A1 (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| TW201938164A (zh) | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
| PL3837263T3 (pl) | 2018-08-13 | 2024-10-14 | F. Hoffmann-La Roche Ag | Nowe związki heterocykliczne jako inhibitory lipazy monoacyloglicerolowej |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| CN114269755A (zh) * | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| PE20221450A1 (es) * | 2019-09-23 | 2022-09-21 | Hoffmann La Roche | Compuestos heterociclicos |
| AR120029A1 (es) * | 2019-09-24 | 2022-01-26 | Hoffmann La Roche | Compuestos heterocíclicos |
| WO2021058443A1 (en) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Fluorescent probes for monoacylglycerol lipase (magl) |
| CR20220118A (es) * | 2019-09-24 | 2022-04-20 | Hoffmann La Roche | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) |
| AU2021338497A1 (en) | 2020-09-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
| CA3234429A1 (en) * | 2021-10-15 | 2023-04-20 | Luc Farmer | Ras inhibitors, compositions and methods of use thereof |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| TW202415651A (zh) | 2022-07-29 | 2024-04-16 | 日商住友製藥股份有限公司 | 含氮飽和雜環衍生物 |
| WO2024061853A1 (en) * | 2022-09-20 | 2024-03-28 | F. Hoffmann-La Roche Ag | Fluorescent probes for magl |
| WO2024168426A1 (en) * | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| CA2609957A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| JP2010519171A (ja) | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | ５−ｈｔ６受容体親和性を有する化合物 |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| AU2012255690B2 (en) | 2011-05-16 | 2015-06-11 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| JP2015508407A (ja) | 2012-01-06 | 2015-03-19 | アビデ セラピューティクス，インク． | カルバメート化合物およびその製造および使用 |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| AU2016261031A1 (en) | 2015-05-13 | 2017-10-05 | Selvita S.A. | Substituted quinoxaline derivatives |
| BR112017024678A2 (pt) | 2015-05-21 | 2018-07-31 | Glaxosmithkline Intellectual Property Development Limited | derivados de benzoimidazol como inibidores de pad4 |
| US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| CN105198903B (zh) * | 2015-11-09 | 2016-08-24 | 代先慧 | 一种治疗急性上呼吸道感染的药物组合物 |
| JP6832342B2 (ja) | 2016-03-31 | 2021-02-24 | 武田薬品工業株式会社 | 複素環化合物 |
-
2019
- 2019-03-22 CA CA3089443A patent/CA3089443A1/en active Pending
- 2019-03-22 SI SI201930519T patent/SI3768684T1/sl unknown
- 2019-03-22 CN CN201980018255.1A patent/CN111936503B/zh active Active
- 2019-03-22 JP JP2020548747A patent/JP7308220B2/ja active Active
- 2019-03-22 PE PE2020001119A patent/PE20201185A1/es unknown
- 2019-03-22 PL PL19711920.9T patent/PL3768684T3/pl unknown
- 2019-03-22 FI FIEP19711920.9T patent/FI3768684T3/fi active
- 2019-03-22 SG SG11202007608UA patent/SG11202007608UA/en unknown
- 2019-03-22 CR CR20200416A patent/CR20200416A/es unknown
- 2019-03-22 KR KR1020207029587A patent/KR20200136425A/ko active IP Right Grant
- 2019-03-22 WO PCT/EP2019/057174 patent/WO2019180185A1/en active Application Filing
- 2019-03-22 LT LTEPPCT/EP2019/057174T patent/LT3768684T/lt unknown
- 2019-03-22 HR HRP20230388TT patent/HRP20230388T1/hr unknown
- 2019-03-22 AU AU2019238381A patent/AU2019238381B2/en not_active Ceased
- 2019-03-22 EP EP19711920.9A patent/EP3768684B1/en active Active
- 2019-03-22 BR BR112020014992-6A patent/BR112020014992A2/pt not_active Application Discontinuation
- 2019-03-22 RS RS20230303A patent/RS64156B1/sr unknown
- 2019-03-22 HU HUE19711920A patent/HUE061584T2/hu unknown
- 2019-03-22 MX MX2020008894A patent/MX2020008894A/es unknown
- 2019-03-22 DK DK19711920.9T patent/DK3768684T3/da active
- 2019-03-22 TW TW108110005A patent/TWI818967B/zh active
- 2019-03-22 ES ES19711920T patent/ES2942319T3/es active Active
-
2020
- 2020-07-13 IL IL276031A patent/IL276031B2/en unknown
- 2020-07-31 CO CONC2020/0009567A patent/CO2020009567A2/es unknown
- 2020-09-08 PH PH12020500661A patent/PH12020500661A1/en unknown
- 2020-09-18 US US17/025,155 patent/US20210107920A1/en not_active Abandoned
- 2020-09-21 CL CL2020002423A patent/CL2020002423A1/es unknown
-
2022
- 2022-08-09 US US17/818,459 patent/US20230117324A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276031A (en) | oxazine monoacylglycerol lipase (magl) inhibitors | |
| ZA202006327B (en) | Magl inhibitors | |
| IL279173A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL289594A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| IL281812A (en) | Monoacylglycerol lipase modulators | |
| IL288936A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| ZA201905934B (en) | Dual magl and faah inhibitors | |
| ZA202007357B (en) | Lipolytic enzyme variants | |
| IL281514B2 (en) | O–glycoprotein–2–acetamido–2–deoxy–3–D–glucopyranosidase inhibitors | |
| PT3768684T (pt) | Inibidores de oxazina da monoacilglicerol lipase (magl) | |
| GB2587631B (en) | An injection lance | |
| PT3894133T (pt) | Um eletrofuso | |
| PT3894132T (pt) | Um eletrofuso | |
| MC200226B1 (fr) | Brique de retenue | |
| GB201903621D0 (en) | Wooltop technology | |
| GB201812462D0 (en) | Inhibitors | |
| GB201801832D0 (en) | Furnace | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |